Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)UnknownNCT02335203
What this trial is testing

The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy

Who this might be right for
Grade 1 Endometrial Endometrioid AdenocarcinomaGrade 2 Endometrial Endometrioid AdenocarcinomaComplex Atypical Endometrial Hyperplasia
Women and Infants Hospital of Rhode Island 76
Not applicableLooking for participantsNCT06689956
What this trial is testing

Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

Who this might be right for
FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid AdenocarcinomaStage IA1 Endometrial Cancer FIGO 2023+1 more
Mayo Clinic 212
Testing effectiveness (Phase 2)Active Not RecruitingNCT05538897
What this trial is testing

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Who this might be right for
FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid AdenocarcinomaMetastatic Endometrial Endometrioid Adenocarcinoma+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT02397083
What this trial is testing

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

Who this might be right for
Atypical Endometrial HyperplasiaFIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
M.D. Anderson Cancer Center 102
Not applicableActive Not RecruitingNCT04604613
What this trial is testing

Prediction of Recurrence Among Low Risk Endometrial Cancer Patients

Who this might be right for
FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
M.D. Anderson Cancer Center 518
Early research (Phase 1)Active Not RecruitingNCT04092270
What this trial is testing

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Who this might be right for
Endometrial High Grade Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+26 more
National Cancer Institute (NCI) 54
Not applicableActive Not RecruitingNCT06213571
What this trial is testing

Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas

Who this might be right for
FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid AdenocarcinomaStage IA Uterine Corpus Cancer AJCC v8+1 more
Mayo Clinic 80
Testing effectiveness (Phase 2)Study completedNCT03300557
What this trial is testing

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Who this might be right for
Atypical HyperplasiaEndometrial Atypical Hyperplasia/Endometrioid Intraepithelial NeoplasiaEndometrial Carcinoma+2 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07349641
What this trial is testing

Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

Who this might be right for
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial NeoplasiaFIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
National Cancer Institute (NCI) 55
Very early researchStudy completedNCT03018249
What this trial is testing

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

Who this might be right for
FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid AdenocarcinomaFIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT01686126
What this trial is testing

Improving the Treatment for Women With Early Stage Cancer of the Uterus

Who this might be right for
Complex Endometrial Hyperplasia With AtypiaGrade 1 Endometrial Endometrioid Adenocarcinoma
Queensland Centre for Gynaecological Cancer 165
96